Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 3/20 | 0.34 |
| ▸ | TK1 | P04183 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17286247 | 0.89 | TK2 (0.38) | TK2TK1ALDH1A1LMNAALB | |
| SCHEMBL17354863 | 0.82 | TK2 (0.39) | TK2TK1ALDH1A1LMNAALB | |
| SCHEMBL17282471 | 0.80 | TK1 (0.40) | TK2TK1 | |
| SCHEMBL15267277 | 0.79 | TK1 (0.34) | TK2TK1 | |
| SCHEMBL16938732 | 0.75 | TK2 (0.37) | TK2TK1ALDH1A1LMNAALB | |
| SCHEMBL17119763 | 0.75 | TK2 (0.37) | TK2TK1ALDH1A1LMNAALB | |
| SCHEMBL18513323 | 0.75 | TK2 (0.49) | TK2TK1ALDH1A1LMNAALB | |
| SCHEMBL11985249 | 0.75 | TK1 (0.33) | TK2TK1 | |
| SCHEMBL15267266 | 0.75 | TK1 (0.33) | TK2TK1 | |
| SCHEMBL15013058 | 0.74 | TK2 (0.40) | TK2TK1ALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337002-A1 | NUCLEOSIDE AND NUCLEOTIDE HAVING SULFONAMIDE STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337002-A1 | NUCLEOSIDE AND NUCLEOTIDE HAVING SULFONAMIDE STRUCTURE | NSUN2, NR2E3, NR0B2 | TK2 209/4885TK1 287/4885ALDH1A1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.